Увійти

Готові списки джерел за темами / Verona diabetes study / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Verona diabetes study.

Статті в журналах з теми "Verona diabetes study"

Автор: Grafiati

Опубліковано: 11 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-44 статей у журналах для дослідження на тему "Verona diabetes study".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

de Marco, R., F. Locatelli, G. Zoppini, G. Verlato, E. Bonora, and M. Muggeo. "Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study." Diabetes Care 22, no. 5 (May 1, 1999): 756–61. http://dx.doi.org/10.2337/diacare.22.5.756.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Brun, E., R. G. Nelson, P. H. Bennett, G. Imperatore, G. Zoppini, G. Verlato, and M. Muggeo. "Diabetes duration and cause-specific mortality in the Verona Diabetes Study." Diabetes Care 23, no. 8 (August 1, 2000): 1119–23. http://dx.doi.org/10.2337/diacare.23.8.1119.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

TROMBETTA, M., G. SPIAZZI, G. ZOPPINI, and M. MUGGEO. "Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study." Alimentary Pharmacology and Therapeutics 22, s2 (November 2005): 24–27. http://dx.doi.org/10.1111/j.1365-2036.2005.02590.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Verlato, G., and M. Muggeo. "Capture-recapture method in the epidemiology of type 2 diabetes: a contribution from the Verona Diabetes Study." Diabetes Care 23, no. 6 (June 1, 2000): 759–64. http://dx.doi.org/10.2337/diacare.23.6.759.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Zoppini, Giacomo, Maddalena Trombetta, Ilaria Pastore, Corinna Brangani, Vittorio Cacciatori, Carlo Negri, Fabrizia Perrone, et al. "Glomerular filtration rate decline in T2DM following diagnosis. The Verona newly diagnosed diabetes study-12." Diabetes Research and Clinical Practice 175 (May 2021): 108778. http://dx.doi.org/10.1016/j.diabres.2021.108778.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Verlato, G., M. Muggeo, E. Bonora, M. Corbellini, F. Bressan, and R. De Marco. "Attending the Diabetes Center Is Associated With Increased 5-Year Survival Probability of Diabetic Patients: The Verona Diabetes Study." Diabetes Care 19, no. 3 (March 1, 1996): 211–13. http://dx.doi.org/10.2337/diacare.19.3.211.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Muggeo, M., G. Verlato, E. Bonora, F. Bressan, S. Girotto, M. Corbellini, M. L. Gemma, et al. "The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality." Diabetologia 38, no. 3 (February 1, 1995): 318–25. http://dx.doi.org/10.1007/s001250050288.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Muggeo, M., G. Verlato, E. Bonora, F. Bressan, S. Girotto, M. Corbellini, M. L. Gemma, et al. "The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality." Diabetologia 38, no. 3 (March 1995): 318–25. http://dx.doi.org/10.1007/bf00400637.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Zoppini, G., G. Verlato, E. Bonora, and M. Muggeo. "Attending the diabetes center is associated with reduced cardiovascular mortality in Type 2 diabetic patients: the Verona Diabetes Study." Diabetes/Metabolism Research and Reviews 15, no. 3 (May 1999): 170–74. http://dx.doi.org/10.1002/(sici)1520-7560(199905/06)15:3<170::aid-dmrr39>3.0.co;2-y.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Zoppini, Giacomo, Giuseppe Verlato, Cristina Zamboni, Cristina Venturi, Nicola Gennaro, Valeria Biasi, Enzo Bonora, and Michele Muggeo. "Pulse Pressure and Mortality from Cerebrovascular Diseases in Type 2 Diabetic Patients: The Verona Diabetes Study." Cerebrovascular Diseases 23, no. 1 (September 12, 2006): 20–26. http://dx.doi.org/10.1159/000095754.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Muggeo, M., G. Zoppini, E. Bonora, E. Brun, R. C. Bonadonna, P. Moghetti, and G. Verlato. "Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study." Diabetes Care 23, no. 1 (January 1, 2000): 45–50. http://dx.doi.org/10.2337/diacare.23.1.45.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Muggeo, M., G. Verlato, E. Bonora, F. Ciani, P. Moghetti, R. Eastman, G. Crepaldi, and R. de Marco. "Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study." Diabetologia 38, no. 6 (May 1, 1995): 672–79. http://dx.doi.org/10.1007/s001250050336.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Muggeo, M., G. Verlato, E. Bonora, F. Ciani, P. Moghetti, R. Eastman, G. Crepaldi, and R. de Marco. "Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study." Diabetologia 38, no. 6 (June 1995): 672–79. http://dx.doi.org/10.1007/bf00401838.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Dalbeni, Andrea, Anna Mantovani, Mirko Zoncapè, Filippo Cattazzo, Michele Bevilacqua, Leonardo De Marco, Veronica Paon, et al. "The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study." PLOS ONE 18, no. 2 (February 16, 2023): e0281813. http://dx.doi.org/10.1371/journal.pone.0281813.

Повний текст джерела

Анотація:

Background and purpose Bacterial infections represent a major cause of morbidity and mortality in cirrhotic patients. Our aim was to assess the incidence of bacterial infections, in particular due to multidrug-resistant organisms (MDROs) before and after the introduction of the antimicrobial stewardship program, “Stewardship Antimicrobial in VErona” (SAVE). In addition, we also analysed the liver complications and the crude mortality during the whole follow up. Methods We analysed 229 cirrhotic subjects without previous hospitalization for infections enrolled at the University Verona Hospital from 2017 to 2019 and followed up until December 2021 (mean follow-up 42.7 months). Results 101 infections were recorded and 31.7% were recurrent. The most frequent were sepsis (24.7%), pneumonia (19.8%), spontaneous bacterial peritonitis (17.8%). 14.9% of infections were sustained by MDROs. Liver complications occurred more frequently in infected patients, and in case of MDROs infections with a significantly higher MELD and Child-Pugh score. In Cox regression analysis, mortality was associated with age, diabetes and bacterial infections episodes (OR 3.30, CI 95%: (1.63–6.70). Despite an increase in total infections over the past three years, a decrease in the incidence rate in MDROs infections was documented concurrently with the introduction of SAVE (IRD 28.6; 95% CI: 4.6–52.5, p = 0.02). Conclusions Our study confirms the burden of bacterial infections in cirrhotic patients, especially MDROs, and the strong interconnection with liver complications. The introduction of SAVE decreased MDROs infections. Cirrhotic patients require a closer clinical surveillance to identify colonized patients and avoid the horizontal spread of MDROs in this setting.

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Trombetta, Maddalena, Sara Bonetti, MariaLinda Boselli, Fabiola Turrini, Giovanni Malerba, Elisabetta Trabetti, PierFranco Pignatti, Enzo Bonora, and Riccardo C. Bonadonna. "CACNA1E Variants Affect Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 3." PLoS ONE 7, no. 3 (March 9, 2012): e32755. http://dx.doi.org/10.1371/journal.pone.0032755.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Bonetti, S., C. Zusi, E. Rinaldi, ML Boselli, A. Csermely, G. Malerba, E. Trabetti, E. Bonora, R. C. Bonadonna, and M. Trombetta. "Role of monogenic diabetes genes on beta cell function in Italian patients with newly diagnosed type 2 diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 13." Diabetes & Metabolism 48, no. 4 (July 2022): 101323. http://dx.doi.org/10.1016/j.diabet.2022.101323.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Zoppini, Giacomo, Vittorio Cacciatori, Daniele Raimondo, Marialuisa Gemma, Maddalena Trombetta, Marco Dauriz, Corinna Brangani, et al. "Prevalence of Cardiovascular Autonomic Neuropathy in a Cohort of Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS)." Diabetes Care 38, no. 8 (June 11, 2015): 1487–93. http://dx.doi.org/10.2337/dc15-0081.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Bonetti, S., M. Trombetta, M. L. Boselli, F. Turrini, G. Malerba, E. Trabetti, P. F. Pignatti, E. Bonora, and R. C. Bonadonna. "Variants of GCKR Affect Both -Cell and Kidney Function in Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study 2." Diabetes Care 34, no. 5 (March 16, 2011): 1205–10. http://dx.doi.org/10.2337/dc10-2218.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Bonora, Enzo, Maddalena Trombetta, Marco Dauriz, Daniela Travia, Vittorio Cacciatori, Corinna Brangani, Carlo Negri, et al. "Chronic complications in patients with newly diagnosed type 2 diabetes: prevalence and related metabolic and clinical features: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 9." BMJ Open Diabetes Research & Care 8, no. 1 (August 2020): e001549. http://dx.doi.org/10.1136/bmjdrc-2020-001549.

Повний текст джерела

Анотація:

IntroductionWe explored the presence of chronic complications in subjects with newly diagnosed type 2 diabetes referred to the Verona Diabetes Clinic. Metabolic (insulin secretion and sensitivity) and clinical features associated with complications were also investigated.Research design and methodsThe comprehensive assessment of microvascular and macrovascular complications included detailed medical history, resting ECG, ultrasonography of carotid and lower limb arteries, quantitative neurological evaluation, cardiovascular autonomic tests, ophthalmoscopy, kidney function tests. Insulin sensitivity and beta-cell function were assessed by state-of-the-art techniques (insulin clamp and mathematical modeling of glucose/C-peptide curves during oral glucose tolerance test).ResultsWe examined 806 patients (median age years, two-thirds males), of whom prior clinical cardiovascular disease (CVD) was revealed in 11.2% and preclinical CVD in 7.7%. Somatic neuropathy was found in 21.2% and cardiovascular autonomic neuropathy in 18.6%. Retinopathy was observed in 4.9% (background 4.2%, proliferative 0.7%). Chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73 m2) was found in 8.8% and excessive albuminuria in 13.2% (microalbuminuria 11.9%, macroalbuminuria 1.3%).Isolated microvascular disease occurred in 30.8%, isolated macrovascular disease in 9.3%, a combination of both in 9.1%, any complication in 49.2% and no complications in 50.8%.Gender, age, body mass index, smoking, hemoglobin A1c and/or hypertension were independently associated with one or more complications. Insulin resistance and beta-cell dysfunction were associated with macrovascular but not microvascular disease.ConclusionsDespite a generally earlier diagnosis for an increased awareness of the disease, as many as ~50% of patients with newly diagnosed type 2 diabetes had clinical or preclinical manifestations of microvascular and/or macrovascular disease. Insulin resistance might play an independent role in macrovascular disease.Trial registration numberNCT01526720.

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Bonetti, S., M. Trombetta, G. Malerba, L. Boselli, E. Trabetti, M. Muggeo, V. Stoico та ін. "Variants and Haplotypes ofTCF7L2Are Associated with β-Cell Function in Patients with Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1". Journal of Clinical Endocrinology & Metabolism 96, № 2 (лютий 2011): E389—E393. http://dx.doi.org/10.1210/jc.2010-1677.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Zoppini, Giacomo, Giuseppe Verlato, Giovanni Targher, Enzo Bonora, Maddalena Trombetta, and Michele Muggeo. "Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study." Diabetes/Metabolism Research and Reviews 24, no. 8 (November 2008): 624–28. http://dx.doi.org/10.1002/dmrr.897.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Dauriz, M., E. Bacchi, L. Boselli, L. Santi, C. Negri, M. Trombetta, R. C. Bonadonna, E. Bonora, and P. Moghetti. "Association of free-living physical activity measures with metabolic phenotypes in type 2 diabetes at the time of diagnosis. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS)." Nutrition, Metabolism and Cardiovascular Diseases 28, no. 4 (April 2018): 343–51. http://dx.doi.org/10.1016/j.numecd.2017.12.011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Pietrobelli, Angelo, Luca Pecoraro, Alessandro Ferruzzi, Moonseong Heo, Myles Faith, Thomas Zoller, Franco Antoniazzi, Giorgio Piacentini, S. Nicole Fearnbach, and Steven B. Heymsfield. "Effects of COVID‐19 Lockdown on Lifestyle Behaviors in Children with Obesity Living in Verona, Italy: A Longitudinal Study." Obesity 28, no. 8 (July 10, 2020): 1382–85. http://dx.doi.org/10.1002/oby.22861.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Bonora, E., G. Targher, G. Formentini, F. Calcaterra, S. Lombardi, F. Marini, L. Zenari, et al. "The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study." Diabetic Medicine 21, no. 1 (January 2004): 52–58. http://dx.doi.org/10.1046/j.1464-5491.2003.01068.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Bonora, E., G. Formentini, F. Calcaterra, S. Lombardi, F. Marini, L. Zenari, F. Saggiani, et al. "HOMA-Estimated Insulin Resistance Is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects: Prospective data from the Verona Diabetes Complications Study." Diabetes Care 25, no. 7 (July 1, 2002): 1135–41. http://dx.doi.org/10.2337/diacare.25.7.1135.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Dauriz, Marco, Maddalena Trombetta, Linda Boselli, Lorenza Santi, Corinna Brangani, Isabella Pichiri, Enzo Bonora, and Riccardo C. Bonadonna. "Interleukin-6 as a potential positive modulator of human beta-cell function: an exploratory analysis—the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 6." Acta Diabetologica 53, no. 3 (November 4, 2015): 393–402. http://dx.doi.org/10.1007/s00592-015-0807-z.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Trombetta, M., M. Dauriz, S. Bonetti, D. Travia, L. Boselli, L. Santi, E. Bonora, and R. C. Bonadonna. "Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with cardiometabolic phenotypes in type 2 diabetes? An exploratory analysis of the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 5." Nutrition, Metabolism and Cardiovascular Diseases 26, no. 3 (March 2016): 232–38. http://dx.doi.org/10.1016/j.numecd.2016.01.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Trombetta, M., S. Bonetti, M. L. Boselli, R. Miccoli, E. Trabetti, G. Malerba, P. F. Pignatti, E. Bonora, S. Del Prato, and R. C. Bonadonna. "PPARG2 Pro12Ala and ADAMTS9 rs4607103 as “insulin resistance loci” and “insulin secretion loci” in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4." Acta Diabetologica 50, no. 3 (November 17, 2012): 401–8. http://dx.doi.org/10.1007/s00592-012-0443-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Targher, Giovanni, Giacomo Zoppini, Giuseppe Lippi, Gian Cesare Guidi, and Michele Muggeo. "Effect of Serum Gamma-Glutamyltransferase and Obesity on the Risk of Dyslipidemia and Poor Glycemic Control in Type 2 Diabetic Patients: Cross-Sectional Findings from the Verona Diabetes Study." Clinical Chemistry 53, no. 10 (October 1, 2007): 1867–69. http://dx.doi.org/10.1373/clinchem.2007.092601.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Corica, Domenico, Chiara Zusi, Francesca Olivieri, Marco Marigliano, Claudia Piona, Elena Fornari, Anita Morandi та ін. "Vitamin D affects insulin sensitivity and β-cell function in obese non-diabetic youths". European Journal of Endocrinology 181, № 4 (жовтень 2019): 439–50. http://dx.doi.org/10.1530/eje-19-0369.

Повний текст джерела

Анотація:

Objective Vitamin D may potentially play a central role in glucose homeostasis and β-cell function (BCF), although studies are not consistent. Aim of our study was to test the hypotheses of a direct relationship between vitamin D, insulin sensitivity (IS) and BCF in overweight and obese non-diabetic children. Design and methods Cross-sectional study carried out at the Childhood Obesity Outpatient Clinic, University Hospital of Verona. One hundred twenty-two Caucasian overweight and obese children (age: 12.8 ± 0.2 years) were enrolled. Exclusion criteria: genetic or endocrine causes of obesity, chronic diseases or therapies. Patients underwent oral glucose tolerance test. HOMA-IR, Matsuda index and insulinogenic index were calculated. BCF was reconstructed by mathematical modeling and described by Derivative and Proportional Control. Total 25-hydroxyvitamin D and vitamin D-binding protein (VDBP) were measured. Two SNPs (rs4588 and rs7041) in the VDBP gene were studied, and bioavailable vitamin D (BVD) was calculated. Results Hypovitaminosis D was documented in 90% of patients. Forty-seven subjects were homozygous for both SNPs. Total vitamin D was positively correlated with Matsuda index (P = 0.002), VDBP (P = 0.045), and negatively with BMI SDS (P = 0.043), HOMA-IR (P = 0.008), HOMA-B (P = 0.001), IGI (P = 0.007), derivative control (P = 0.036) and proportional control (P = 0.018). Total vitamin D, adjusted for age, gender, BMI SDS, puberty and seasonality of vitamin D measurement, was a predictor of Matsuda index, HOMA-IR, HOMA-B, IGI, proportional control (all P < 0.05). BVD was positively correlated with total vitamin D (P < 0.001) and negatively with BMI SDS (P = 0.041). Conclusions Hypovitaminosis D negatively influences BCF and IS, suggesting that vitamin D levels might be implicated in glucose metabolism impairment in overweight and obese individuals.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Bonetti, Graziella, Nicola Di Gaetano, Renata Paleari, and Ferruccio Ceriotti. "Effects of different anticoagulants on glycated albumin quantification." Biochemia medica 29, no. 1 (December 24, 2018): 138–41. http://dx.doi.org/10.11613/bm.2019.010901.

Повний текст джерела

Анотація:

Introduction: In the last 20 years glycated albumin (GA) measurement has been demonstrated to be a reliable glycation marker and recently as the most innovative one in western countries. Glycated albumin has been already adopted by some Asian countries due to its usefulness in diabetes screening. The aim of the present study was to investigate for the first time the effects of different anticoagulants on GA assay. Materials and methods: From each of 60 patients a serum tube and K3EDTA, Li-Heparin and NaF-EDTA containing tubes were collected. All tubes were from Sarstedt (Verona, Italy). Glycated albumin was measured in duplicate in each sample tube in a single analytical run with quantILab glycated albumin (Instrumentation Laboratory SpA - A Werfen Company, Milan, Italy) on Architect c8000 analyser (Abbott SRL, Rome, Italy). Comparison of GA% in evaluated tubes was made by paired Wilcoxon test. Results: Median and interquartile range GA% concentrations were 15.4% (13.2 - 19.1) in serum, 15.7% (13.6 - 19.9) in K3EDTA, 15.6% (13.3 - 19.7) in Li-heparin and 15.5% (13.1 - 19.3) in NaF-EDTA samples, respectively. Glycated albumin mean relative bias respect to serum was within desirable bias derived from biological variation studies (± 2.9%) when K3EDTA (+ 2.8%), Li-heparin (+ 0.9%) or NaF-EDTA (+ 0.1%), were used as anticoagulants. Conclusions: Our results demonstrate that the GA% assay is not affected by relevant interferences when K3EDTA, Li-heparin or NaF-EDTA are used as anticoagulants, so they can be used interchangeably without a relevant impact on the clinical use of the test.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Schroer, W. C., A. R. LeMarr, K. Mills, A. L. Childress, D. J. Morton, and M. E. Reedy. "2019 Chitranjan S. Ranawat Award: Elective joint arthroplasty outcomes improve in malnourished patients with nutritional intervention." Bone & Joint Journal 101-B, no. 7_Supple_C (July 2019): 17–21. http://dx.doi.org/10.1302/0301-620x.101b7.bjj-2018-1510.r1.

Повний текст джерела

Анотація:

Aims To date, no study has demonstrated an improvement in postoperative outcomes following elective joint arthroplasty with a focus on nutritional intervention for patients with preoperative hypoalbuminaemia. In this prospective study, we evaluated differences in the hospital length of stay (LOS), rate of re-admission, and total patient charges for a malnourished patient study population who received a specific nutrition protocol before surgery. Patients and Methods An analytical report was extracted from the electronic medical record (EMR; Epic, Verona, Wisconsin) of a five-hospital network joint arthroplasty patient data set between 2014 and 2017. A total of 4733 patients underwent joint arthroplasty and had preoperative measurement of albumin levels: 2220 at four hospitals and 2513 at the study hospital. Albumin ≤ 3.4 g/l, designated as malnutrition, was found in 543 patients (11.5%). A nutritional intervention programme focusing on a high-protein, anti-inflammatory diet was initiated in January 2017 at one study hospital. Hospital LOS, re-admission rate, and 90-day charges were compared for differential change between patients in study and control hospitals for all elective hip and knee arthroplasty patients, and for malnourished patients over time as the nutrition intervention was implemented. Results Malnourished patients with nutritional intervention at the study hospital had shorter hospital LOS beginning in 2017 than malnourished patients at control hospitals during the same period (p = 0.04). Similarly, this cohort had significantly lower primary hospitalization charges, charges associated with hospital re-admissions, and 90-day total charges (p < 0.001). Inclusion of covariant potential confounders (age, anaemia, diabetes, and obesity) did not alter the conclusions of the primary statistical analysis. Conclusion Joint arthroplasty outcomes were positively affected in study patients with low albumin when a high-protein, anti-inflammatory diet was encouraged. Elective surgery was neither cancelled nor delayed with a malnutrition designation. While the entire network population experienced improved postoperative outcomes, malnourished control patients did not experience this improvement. This study demonstrated that education on malnutrition can benefit patients. Cite this article: Bone Joint J 2019;101-B(7 Supple C):17–21

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Marchegiani, Giovanni, Luca Landoni, Stefano Andrianello, Gaia Masini, Sara Cingarlini, Mirko D’Onofrio, Riccardo De Robertis, et al. "Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and Where?" Neuroendocrinology 108, no. 3 (November 27, 2018): 161–71. http://dx.doi.org/10.1159/000495774.

Повний текст джерела

Анотація:

Background/Aims: Pancreatic neuroendocrine tumors (pan-NENs) represent an increasingly common indication for pancreatic resection, but there are few data regarding possible recurrence after surgery. The aim of the study was to describe the frequency, timing, and patterns of recurrence after resection for pan-NENs with consequent implications for postoperative follow-up. Methods: We performed a retrospective analysis of pan-NENs resected between 1990 and 2015 at The Pancreas Institute, University of Verona Hospital Trust. Predictors of recurrence were assessed. Survival analysis was conducted using the Kaplan-Meier and conditional survival (CS) methods. Results: The cohort consisted of 487 patients with a median follow-up of 71 months. Recurrence developed in 12.3%: 54 (11.1%) liver metastases, 11 (2.3%) local recurrence, 10 (2.1%) nodal recurrence, and 8 (1.6%) metastases in other organs. Thirty-one (6.4%) died due to disease recurrence. Size > 21 mm, G3 grade, nodal metastasis, and vascular infiltration were independent predictors of overall recurrence. Recurrence occurred either during the first year of follow-up (n = 9), or after 10 years (n = 4). CS analysis revealed that nonfunctioning G1 pan-NEN ≤20 mm without nodal metastasis or vascular invasion had a negligible risk of developing recurrence. In the present series, after 5 years of follow-up without developing recurrence, tumor recurrence occurred only in the form of liver metastases. Conclusions: Recurrence of pan-NENs is rare and is predicted by tumor size, nodal metastasis, grading, and vascular invasion. Patients with G1 pan-NEN without nodal metastasis and vascular invasion may be considered cured by surgery. After 5 years without recurrence, follow-up should focus on excluding the development of liver metastases.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Adami, G., A. Fassio, A. Giollo, G. Orsolini, O. Viapiana, D. Gatti, and M. Rossini. "SAT0456 REAL-LIFE RISK OF FRACTURE AND TREATMENT PREVALENCE IN DRUG-INDUCED OSTEOPOROSIS IN ITALY USING A NEW ALGORITHM." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1185.1–1186. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2565.

Повний текст джерела

Анотація:

Background:Glucocorticoid-induced osteoporosis and osteoporosis induced by adjuvant hormone therapy for breast cancer are the most common forms of secondary osteoporosis.Objectives:The exact real-life prevalence of treatment with anti-osteoporotic drugs in women with drug-induced osteoporosis is not known. In the present study, using a new mathematical and computerized algorithm, we investigate the profile of risk of fracture of women with drug-induced osteoporosis and the prevalence of treatment with anti-osteoporotic drugs.Methods:We have retrospectively analyzed the 10-year risk of major osteoporotic fracture calculated with the DeFRAcalc79 tool in postmenopausal women aged over 50 years that were initiating an anti-osteoporotic treatment (fully reimbursed according to the Nota 79). DeFRAcalc79 is a new web-based fracture risk-assessment tool (https://defra-osteoporosi.it) that arithmetically adjusts the risk based on multiple risk factors contemplated by the Nota 79, which regulates the reimbursability for osteoporosis medications in Italy (Italian Agency for Drugs, AIFA), including demographic and anthropometric data, femoral and/or lumbar spine BMD T-score, family history of femoral or vertebral fractures, number and site of previous osteoporotic fracture (including vertebral, femoral, and non-vertebral non-femoral fractures), glucocorticoid treatment (> 3 or > 12 months, ≥5 mg prednisone or equivalent), adjuvant hormone therapy for breast cancer, and comorbidities that induce an increased risk of fracture (rheumatoid arthritis and other connective tissue diseases, chronic obstructive pulmonary disease, inflammatory bowel diseases, Parkinson’s disease, multiple sclerosis, human immunodeficiency virus infection, diabetes, or severe physical handicap). This is a sub-analysis of the cross-sectional observational study to validate and further develop the DeFRA algorithm for the estimation of the risk of osteoporotic fractures, promoted by Verona hospital with the unconditional support of Amgen Srl.Results:Among 208 women, 116 (55.8%) were treated with adjuvant hormone therapy for breast cancer and 92 (44.2%) were on glucocorticoid ≥5 mg/day. Women on glucocorticoids had a greater mean 10-year risk of fracture compared to women on adjuvant hormone therapy for breast cancer (67.0% vs 39.1% p<0.01). 50.7% of women on adjuvant hormone therapy for breast cancer used denosumab, 28.0% zoledronic acid and 17.3% alendronate. In glucocorticoid-induced osteoporosis, 17.6% of the women used teriparatide, 37.3% alendronate, 29.4% zoledronic acid and 13.7% denosumab.Conclusion:In our cohort of patients, treatment with adjuvant hormone therapy for breast cancer was slightly more common than glucocorticoids. Women with glucocorticoid-induced osteoporosis had a greater risk of fracture compared to patients treated with adjuvant hormone therapy for breast cancer. Half of the patients on adjuvant hormone therapy for breast cancer were prescribed with denosumab. One-fifth of the patients with glucocorticoid-induced osteoporosis was treated with teriparatide. DeFRAcalc79 is a useful and practical tool for the integrated evaluation of fracture risk in drug-induced osteoporosis.Disclosure of Interests:Giovanni Adami: None declared, Angelo Fassio Speakers bureau: Angelo Fassio reports personal fees from: Abiogen and Novartis, outside the submitted work., Alessandro Giollo: None declared, Giovanni Orsolini: None declared, Ombretta Viapiana: None declared, Davide Gatti Speakers bureau: Davide Gatti reports personal fees from Abiogen, Amgen, Janssen-Cilag, Mundipharma, outside the submitted work., Maurizio Rossini Speakers bureau: AbbVie, Abiogen, Amgen, BMS, Eli-Lilly, Novartis, Pfizer, Sanofi, Sandoz and UCB

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Martinelli, Nicola, Domenico Girelli, Marcello Baroni, Patrizia Guarini, Federica Tosi, Barbara Lunghi, Barry J. Woodhams, Francesco Bernardi, and Oliviero Olivieri. "Activated Factor VII–Antithrombin Complex Plasma Concentration Is An Independent Predictor Of Total and Cardiovascular Mortality In Patients With Coronary Artery Disease and Its Prognostic Significance Is Improved By Using Factor VII Genotype-Specific Threshold Levels." Blood 122, no. 21 (November 15, 2013): 2339. http://dx.doi.org/10.1182/blood.v122.21.2339.2339.

Повний текст джерела

Анотація:

Abstract Introduction Plasma concentration of activated factor VII (FVIIa)-antithrombin (AT) complex has recently been proposed as a marker of intravascular exposure of tissue factor (TF) and, thus, of activation of the extrinsic pathway of coagulation cascade. However, the results of studies investigating the potential relationship between FVIIa-AT complex and coronary artery disease (CAD) are only preliminary so far. The aim of this study was to investigate the predictive value of FVIIa-AT plasma concentration for total and cardiovascular mortality in the setting of secondary prevention of CAD. Methods Within the framework of the Verona Heart Study (VHS), we selected a cohort of 510 patients with angiographically proven CAD (mean age 61.8±10.6 years; females 23.7%), who were not taking anticoagulant drugs at time of enrolment and for whom plasma citrate samples for FVIIa-AT assay were available. These patients were prospectively followed for a median period of 64 months. Plasma concentration of FVIIa-AT complex was determined by ELISA. Moreover, patients were genotyped for FVII -323 del/ins (A1/A2) promoter polymorphism. Results The majority of patients had severe CAD and received surgical or endovascular coronary revascularization during the period 1999–2006 (81.8%). Eight patients had peri-operative deaths and were excluded from subsequent analyses. During follow-up, 105 (20.9%) subjects died, with 68 (13.5%) events attributed to cardiovascular causes. CAD patients who died had a significantly higher plasma concentration of FVIIa-AT than those survived (P=0.002). Stratifying the study population on the basis of the FVIIa-AT quartiles, we noted an evident increase of both total and cardiovascular mortality for the subjects in the two upper quartiles (Figure 1A). CAD patients with plasma concentration of FVIIa-AT higher than the median value (79 pM) had an increase in both total and cardiovascular mortality than those with lower values (26.7% versus 15.0%, P=0.001, and 17.3% versus 9.7%, P=0.006 by Log Rank tests, respectively). After adjustment for the other predictors of mortality at univariate analysis (i.e. sex, age, number of coronary vessels involved, MI history, hypertension, diabetes, BMI, renal function, and hs-CRP concentration), elevated FVIIa-AT (≥79 pM) significantly predicted both total and cardiovascular mortality (HR for total and cardiovascular mortality: 2.24 (1.35-3.70) and 1.92 (1.02-3.61), respectively). Such associations remained significant also after adjustment for left ventricular ejection fraction (HR for total and cardiovascular mortality: 1.91 (1.21-3.03) and 1.86 (1.03-3.34), respectively), as well as for the main cardiovascular therapies at discharge, like beta-blockers, ACE-inhibitors, statins, and antiplatelet/anticoagulant drugs (HR for total and cardiovascular mortality: 1.67 (1.08-2.59) and 1.77 (1.01-3.11), respectively). In a subgroup of subjects for whom data of FVIIa were available (n=191), FVIIa-AT concentration remained significantly associated with mortality, while FVIIa levels had no prognostic role. The FVII -323 del/ins (A1/A2) promoter polymorphism is well know to be associated with FVII/FVIIa levels. The A2 allele, that results in a decrease of FVIIa levels, was consistently associated with lower FVIIa-AT plasma concentration in our study-population (71.5 pM in A2 carriers versus 89.3 pM in A1A1 homozygous carriers, P<0.001 by t-test). Remarkably, the predictive model of FVIIa-AT plasma concentration appeared to be improved when stratified on the basis of FVII genotype-specific threshold levels (Figure 1B - HR 2.57 (1.36-4.85) comparing the highest versus the lowest quartile according genotype-specific thresholds, while the HR was 1.95 (1.07-3.53) according whole population thresholds). Conclusions In this study high plasma concentrations of FVIIa-AT complex were an independent predictor of both total and cardiovascular mortality in patients with angiographically demonstrated CAD, speculatively reflecting a prothrombotic diathesis due to TF-related activation of coagulation cascade. Moreover, the predictive model appeared to be improved by using FVII genotype-specific threshold levels of FVIIa-AT concentration, addressing the interest on TF-related pathways. In summary, FVIIa-AT plasma concentration may be a useful prognostic marker in the setting of secondary prevention of CAD. Disclosures: No relevant conflicts of interest to declare.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Lee, Young-Sil, Won-Kyung Yang, Hwa Kim, Bokkee Min, Nuria Caturla, Jonathan Jones, Yang-Chun Park, Young-Cheol Lee, and Seung-Hyung Kim. "Metabolaid® Combination of Lemon Verbena and Hibiscus Flower Extract Prevents High-Fat Diet-Induced Obesity through AMP-Activated Protein Kinase Activation." Nutrients 10, no. 9 (September 1, 2018): 1204. http://dx.doi.org/10.3390/nu10091204.

Повний текст джерела

Анотація:

Lemon verbena (Lippia citriodora) has been used as a food spice, cosmetic, and in traditional medicine formulations to treat asthma and diabetes in South America and Southern Europe. Hibiscus flower (Hibiscus sabdariffa L.) is used in traditional Chinese medicine in the form of a tea to treat hypertension and inflammation. In the present study, we examined the synergistic effects of a formula of Metabolaid® (MetA), a combination of lemon verbena and hibiscus-flower extracts, on obesity and its complications in high-fat-diet (HFD)-induced obese mice. The results showed that MetA decreased body weight, white adipose tissue (WAT), and liver weight. Additionally, serum and hepatic lipid profiles, glucose levels, glucose tolerance, and cold-induced thermogenesis were significantly improved. Appetite-regulating hormones adiponectin and leptin were significantly increased and decreased, respectively, while the inflammatory-related factors tumor necrosis factor (TNF)-α and interleukin (IL)-6 were downregulated by MetA. Adipogenesis-activating gene expression was decreased, while increased thermogenesis-inducing genes were upregulated in the WAT, correlating with increased phosphorylation of AMPK and fatty-acid oxidation in the liver. Taken together, these results suggest that MetA decreased obesity and its complications in HFD mice. Therefore, this formula may be a candidate for the prevention and treatment of obesity and its complications.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Petrankov, K. V., V. V. Salukhov, and M. I. Pugachev. "Comparative assessment of the prognostic value of mathematical models in determining the risk of developing type 2 diabetes mellitus." Meditsinskiy sovet = Medical Council, no. 14 (August 12, 2022): 128–36. http://dx.doi.org/10.21518/2079-701x-2022-16-14-128-136.

Повний текст джерела

Анотація:

Introduction. Early relevant is the early prediction of the development of type 2 diabetes (T2D), which allows to prevent the development of the disease and its complications. For the purpose of screening, scales for assessing the risk of its development based on the results of questionnaires are used, but at the moment there are no questionnaires against employees of law enforcement agencies professionally related to psycho-emotional stress.Aim. Assessment of the prognostic value of the original mathematical model of the VERADIV to assess the risk of developing T2D in comparison with the FINDRISC questionnaires and a DIARISK regarding the cohort of military personnel.Materials and methods. 212 subjects from among military personnel under a young and middle -aged contract with a waist of the a avyinary poles and a representative control group from among civilians (60 people) were selected for prospective cohort research. At the first stage of the study, anthropometric psychophysiological indicators were studied, as well as laboratory data aimed at assessing the state of the endocrine function of the pancreas and the degree of insulin resistance. After 3 years, the state of carbohydrate exchange of subjects with the assessment of factors that influenced the development of new cases of prediabetes and T2D was evaluated. Based on the data obtained, an index of the VERADIV was developed, avaluating the likelihood of risk of developing T2D among military personnel. The most important stage in the work was a comparative assessment of the prognostic value of the model of the FINDRISC verasa and the DIARISK, set forth in this article.Results and discussion. The mathematical model of predicting the risk of T2D, from the age, from the HOMA-IR index, allows the points of aggressiveness and volitional self -control in 91.9% of cases, correctly predict the absence of the development of T2D after 3 years, and during the same period the probability of manifestation of T2D – in 91.7% of cases. For cohorts of military personnel, the specificity and sensitivity of the FINDRISC questionnaire amounted to 69.5 and 75%, respectively. The specificity and sensitivity of the DIARISK questionnaire amounted to 75%.Conclusion. The results of the study indicate the importance of taking into account insulin resistance and psycho-emotional stress in assessing the risk of developing T2D among military personnel, which confirmed the high prognostic value of the vendiv scale.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

LI, YISHA, REBECCA B. CONWAY, KENDRA YOUNG, KATHERINE A. PRATTE, DINAH FOER, STEPHEN RENNARD, ERIN AUSTIN, YEONGJIN GWON, and GREGORY L. KINNEY. "1238-P: Diabetes Treatment Using Metformin Is Associated with Protective Effect for Emphysema Progression in Smokers." Diabetes 71, Supplement_1 (June 1, 2022). http://dx.doi.org/10.2337/db22-1238-p.

Повний текст джерела

Анотація:

Rationale: Type 2 Diabetes (T2D) is one of the leading chronic diseases among smokers. Chronic obstructive pulmonary disease (COPD) is common among people with diabetes, with the lung posited as an additional target organ of diabetes. Previous literature suggests that some medications treating comorbidities of COPD patients may also benefit lung function. Objectives: We used a novel statistical method to identify comorbidity medications associated with pulmonary function progression and assess potential effects using an adjusted mixed effect model among smokers with and without COPD. Methods: Participants from the COPDGene cohort who completed initial visit (P1) , and 5-year follow up (P2) from 20through 2017 with complete demographics, clinical information, and medication history were included in the study. A least absolute shrinkage and selection operator (LASSO) model with false discovery rate control by a knockoff filter was used to identify medication classes associated with COPD progression in participants with and without T2D treatment. An adjusted linear mixed model was then used to confirm the association between selected medication and the change in percent emphysema and other lung function variables from P1 to P2. Results: A total of 3,786 out of 10,198 smokers with complete information from P1 and P2 were included. Overall, 359 out of 3,786 smokers reported having T2D at P1, 2out of 359 patients were treated with the class of biguanides (metformin) at P1. The LASSO selection identified metformin as strongly associated with percent emphysema change. Adjusted linear mixed models confirmed that metformin use is associated with the reduction of emphysema in smokers (p<0.0001) from P1 to P2. Conclusions: Our study identified and confirmed an association between metformin and reduced emphysema progression among smokers with and without COPD. Metformin, a common treatment for diabetes, may also have protective effect on lung function. Disclosure Y.Li: Employee; Vertex Pharmaceuticals Incorporated. R.B.Conway: None. K.Young: None. K.A.Pratte: None. D.Foer: Research Support; IBM Watson Health. S.Rennard: Advisory Panel; GlaxoSmithKline plc., Sanofi, Verona, Verona, Consultant; Bergenbio, Boehringer Ingelheim International GmbH, NovoVentures. E.Austin: None. Y.Gwon: None. G.L.Kinney: None. Funding U01HL089897U01HL089856

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Tagetti, Angela, Claudia A. Piona, Denise Marcon, Alice Giontella, Lorella Branz, Stefano Bortolotti, Anita Morandi, Claudio Maffeis, and Cristiano Fava. "Central Systolic Blood Pressure Is Associated With Early Vascular Damage in Children and Adolescents With Type 1 Diabetes." Frontiers in Cardiovascular Medicine 8 (September 7, 2021). http://dx.doi.org/10.3389/fcvm.2021.606103.

Повний текст джерела

Анотація:

Objective of the study: This study aimed to test the effect of multiple cardiovascular risk factors on subclinical indices of atherosclerosis in children and adolescents with type 1 diabetes (T1D).Methods: Carotid intima-media thickness (cIMT), carotid distensibility coefficient (cDC), and carotid–femoral pulse wave velocity (PWV) were measured in children and adolescents with T1D, in a follow-up at the outpatient clinics of Verona. Blood pressure (BP; both central and peripheral), metabolic and other cardiovascular risk factors were evaluated in multivariate linear regressions to assess the association with the measured indices of subclinical vascular damage.Results: One hundred and twenty-six children and adolescents were included. cIMT was above the 95th percentile for age and height in 60.8% of the population, whereas 26% of the sample had cDC impairment (less than the 5th percentile) and 4.8% had an elevated PWV. Independent determinants of cIMT according to the regression models were only gender type of glucose monitoring and central systolic BP (cSBP). PWV was associated with age, sex, heart rate, and cSBP; cDC with age and both cSBP and, alternatively, peripheral BP (pBP). Neither pBP nor any of the tested metabolic parameters, including glycated hemoglobin, was associated with PWV and cIMT.Conclusions: A high proportion of early vascular damage, especially an increased cIMT, is present in children and adolescents with T1D in whom cSBP seems to be a common determinant. In children and adolescents with T1DM, a special focus should be on hemodynamic risk factors beyond metabolic ones.

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Liu, Kai, Alimujiang Abulaiti, Yanshi Liu, Feiyu Cai, Peng Ren, and Aihemaitijiang Yusufu. "Risk factors of pin tract infection during bone transport using unilateral external fixator in the treatment of bone defects." BMC Surgery 21, no. 1 (October 26, 2021). http://dx.doi.org/10.1186/s12893-021-01384-z.

Повний текст джерела

Анотація:

Abstract Background The bone transport using the unilateral external fixator, one of the Ilizarov techniques, is widely practiced in lower limb reconstructive surgery. Pin tract infection (PTI), one of most common complication, has become the important postoperative problems which plague clinicians gradually. Methods A group of 130 patients who received bone transport surgery for tibia or femur defects using the unilateral external fixation (Orthofix limb reconstruction system, Verona, Italy) and met the inclusion criteria were selected for the study from 2015 to 2019. Regular pin tract care was performed twice a day, and the conditions of the pin tract were evaluated by the same observer using clinical appearance criteria. The Saw’s classification of PTI was used to assess the condition around screws. After the data were significant by the T-test or Pearson’s Chi-square test analyzed, odds ratios were calculated using logistic regression tests to describe factors associated with the diagnosis of PTI. Results Ninety-one males and thirty-nine females with a mean age of 43 years (range 28–58 years) were included in this cohort. 7816 observations were documented from 12 to 36 months, and 58 cases (44.6%) of PTI (thirty-nine cases in grade 1, 17 cases in grade 2, and 2 cases in grade 3). The top five risk factors were agricultural work (OR 1.86, CI 0.94–2.39), non-urban living (OR 1.75, CI 1.24–3.26), male (OR 1.71, CI 1.02–2.31), smoking (OR 1.53, CI 0.76–1.89), and diabetes (OR 1.26, CI 1.12–2.64). No long-term sequelae were observed at the latest clinical visit. Conclusion Occupation, gender, living environment (non-urban), smoking, and diabetes were the top five significant risk factors for PTI in the period of bone transport using unilateral external fixation. Awareness of predictable risk factors of PTI is beneficial to avoid or early detect the severe complications which can affect the effectiveness.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Dinesh, Anant, Taha Mallick, Tatiana M. Arreglado, Brian L. Altonen, and Ryan Engdahl. "Outcomes of COVID-19 Admissions in the New York City Public Health System and Variations by Hospitals and Boroughs During the Initial Pandemic Response." Frontiers in Public Health 9 (May 11, 2021). http://dx.doi.org/10.3389/fpubh.2021.570147.

Повний текст джерела

Анотація:

Introduction: In the initial pandemic regional differences may have existed in COVID-19 hospitalizations and patient outcomes in New York City. Whether these patterns were present in public hospitals is unknown. The aim of this brief study was to investigate COVID-19 hospitalizations and outcomes in the public health system during the initial pandemic response.Methods: A retrospective review was conducted on COVID-19 admissions in New York City public hospitals during the exponential phase of the pandemic. All data were collected from an integrated electronic medical records system (Epic Health Systems, Verona, WI). Overall, 5,422 patients with at least one admission each for COVID-19 were reviewed, with a study of demographic characteristics (including age, gender, race, BMI), pregnancy status, comorbidities, facility activity, and outcomes. Data related to hospitalization and mortality trends were also collected from City of New York website. These data often involved more than one facility and/or service line resulting in more location or treatment facility counts than patients due to utilization of services at more than one location and transfers between locations and facilities.Results: Higher mortality was associated with increasing age with the highest death rate (51.9%) noted in the age group >75 years (OR 7.88, 95%CI 6.32–10.08). Comorbidities with higher mortality included diabetes (OR 1.5, 95% CI 1.33–1.70), hypertension (OR 1.62, 95% CI 1.44–1.83), cardiovascular conditions (OR 1.66, 95% CI 1.47–1.87), COPD (OR 1.86, 95% CI 1.39–2.50). It was deduced that 20% of all New York City COVID-19 positive admissions were in public health system during this timeframe. A high proportion of admissions (21.26%) and deaths (19.93%) were at Elmhurst Hospital in Queens. Bellevue and Metropolitan Hospitals had the lowest number of deaths, both in borough of Manhattan. Mortality in public hospitals in Brooklyn was 29.9%, Queens 28.1%, Manhattan 20.4%.Conclusion: Significant variations existed in COVID-19 hospitalizations and outcomes in the public health system in New York City during the initial pandemic. Although outcomes are worse with older age and those with comorbidities, variations in hospitals and boroughs outside of Manhattan are targets to investigate and strategize efforts.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Del Sole, Paolo Alberto, Simone Fezzi, Concetta Mammone, Massimo Flaim, Mattia Lunadi, Roberto Scarsini, Domenico Tavella, Gabriele Pesarini, Michele Pighi, and Flavio Luciano Ribichini. "961 RIGHT VENTRICLE-PULMONARY ARTERY COUPLING RATIO AS PROGNOSTIC FACTOR FOR PATIENTS WITH SEVERE AORTIC STENOSIS UNDERGOING TAVI." European Heart Journal Supplements 24, Supplement_K (December 14, 2022). http://dx.doi.org/10.1093/eurheartjsupp/suac121.732.

Повний текст джерела

Анотація:

Abstract Background Right Ventricle/Pulmonary Artery (RV/PA) coupling has recently emerged as a relevant prognostic factor in patients undergoing transcatheter valvular interventions. The aim of this study is to assess the interaction between RV/PA coupling ratio and the incidence of Acute Kidney Injury (AKI) following TAVI in patients with severe aortic stenosis. Furthermore we investigated the interaction between this novel ratio and adverse events at 24 months follow-up. Methods A population of 283 patients was selected from the Verona Valvular Registry (CESC n =1918). RV/PA coupling was estimated as the ratio of tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PAPs) obtained through transthoracic echocardiograms. AKI was defined as an increase in serum creatinine (sCr) of at least 0.3 mg/dL up to 48 hours following TAVI. Major adverse cardiovascular events (MACEs) were defined as the composite occurrence of cardiac death, re-hospitalization for congestive heart failure and stroke. Results Mean age was 83.4 ± 5.36 years and 41.3% of patients were female. The median value of TAPSE/PAPs ratio was 0.5667 mm/mmHg and was used as a cut-off. A TAPSE/PASP ratio <0.5667 was found to be associated with a higher incidence of MACE at Kaplan Meyer analysis at 24 months (10.4% vs 3.5%, log p = 0.004) and higher occurrence of AKI (17.0% vs. 7.7%; p=0.027). Notably TAPSE/PAPs interquartile comparison showed higher incidence for AKI in patients in the lowest quartile compared to higher ones (24.2% vs. 8.5%; p = 0.001). Following Cox multivariate analysis, TAPSE/PAPs ratio and diabetes mellitus were found to be independent predictors of AKI. Furthermore, risk for 24 months MACEs was higher in the population with lower TAPSE/PAPs ratio (HR 2.672; CI 95% [1.195–5.974]; p = 0.017). Conclusion RV/PA coupling, as characterized by TAPSE/PAPs ratio, is a promising independent predictor of AKI, also associated with higher risk of major adverse cardiac events at follow-up in subjects undergoing TAVI. These data suggest a possible role for this novel index in risk stratification, assessment of the prognosis, and decision-making in these patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Chrystomo, Linus Yhani, I. Made Budi, and Aditya Krishar Karim. "PEMANFAATAN DAN CARA MERACIK HERBAL TUMBUHAN OBAT ANTIDIABETES DAUN AFRIKA (Vernona amygdalina DELILE) DI KABUPATEN KEEROM PAPUA." JURNAL PENGABDIAN PAPUA 2, no. 3 (January 25, 2019). http://dx.doi.org/10.31957/.v2i3.658.

Повний текст джерела

Анотація:

Community service with the title: Utilization and how to formulate medicinal plant of African leaf (Vernonia amygdalina Delile) in Keerom Papua, aims to provide the skills of Arsopura Village community in Skamto District of Keerom Regency. The aims to this activities is the use and how to formulate antidiabetic medicinal plants. Diabetes mellitus is a disease caused due to metabolic disorders of the body, where the sugar content in the body can not be catalyzed by the enzyme insulin which was produced the pancreas gland. Herbal antidiabetes formulated from African leaf plants is a traditional knowledge based on local wisdom Kerom community hereditary used to cure diabetes melitus diseases. This activities is an effort to raise the local wisdom about traditional medicine that has been empirically or hereditary has been used as a traditional medicine antidiabetes. Utilization of herbs of traditional medicinal plants need to be socialized by providing skills how to use it and how to formulate to local communities in the Arsopura Village, Keerom regency according to the guidelines regulation of the Supervision of Food and Drug Indonesian Government about the Making of Good Traditional Drugs (CPOTB). According to Institution of Supervision of Food and Drug Indonesian Government that traditional medicine has been used for from generation to generation can be used by the community without having to get permission from The Institution of Supervision of Food and Drug Indonesian Government. Traditional medicine must also have the criteria of safety, quality and efficacy. The purpose of this activities is to provide knowledge on how to utilize and skill how to use herbs of traditional African antidiabetes leaf medicine in Keerom Regency. The method of education used is the lecture or extension method of herbal medicine utilization of traditional antidiabetic medicinal plants, how to use and how to cultivate it. The result data of this activities can be concluded that local people in Arsopura Village, Keerom Regency are very enthusiastic to study the utilization of traditional antidiabetes leaf medicinal plants of Africa and how to mix herbs of traditional antidiabetic medicinal plants and how to cultivate them as Medicinal Plants for family (TOGA). The answer of the question post increasingly and extends to various diseases and herbs that can be used to other disease. Suggestions need assistance in mixing herbs traditional antidiabetes medicinal plants and how to cultivate these plants.Keywords: Herbs, antidiabetes, Vernonia amygdalina, diabetes mellitus, Keerom

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Li, Bo, Xuesong Wang, Xin Gao, Xuan Ma, Leilei Zhang, Jun Mei, and Jing Xie. "Shelf-Life Extension of Large Yellow Croaker (Larimichthys crocea) Using Active Coatings Containing Lemon Verbena (Lippa citriodora Kunth.) Essential Oil." Frontiers in Nutrition 8 (July 20, 2021). http://dx.doi.org/10.3389/fnut.2021.678643.

Повний текст джерела

Анотація:

Active coating could improve the fish quality and extend the shelf life. This study investigates the effect of locust bean gum (LBG) and sodium alginate (SA) active coatings containing lemon verbena (Lippa citriodora Kunth.) essential oil (LVEO) emulsions on microbiological, physicochemical and organoleptic evaluation of large yellow croaker (Larimichthys crocea) samples during refrigerated storage at 4°C. Results showed that LBG-SA coatings incorporated with 0.30 or 0.60% LVEO emulsions significantly inhibited the growth of mesophile bacteria, Pseudomonas spp., H2S-producing bacteria, lactic acid bacteria (LAB) and psychrophilic bacteria, and reduce the productions of trimethylamine (TMA), total volatile basic nitrogen (TVB-N) and ATP-related compounds. Further, the LVEO treatments also retarded the water migration and maintained the organoleptic evaluation results of large yellow croaker during storage at 4°C. In conclusion, the LBG-SA active coatings incorporated with LVEO emulsions maintained the quality and extended the shelf life of large yellow croaker during refrigerated storage.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!